Search Results
Your search for all items matches 34730 pages
Showing 25101 - 25150
Asher Chanan-Khan, MD, Summarizes Ibrutinib, Bendamustine, and Rituximab in Previously Treated CLL/SLL
Asher Alban Chanan-Khan, MD, of the Mayo Clinic Cancer Center, discusses an important treatment option that significantly improved overall response rate and reduced risk of progression or death by 80% (Abstract LBA7005).
Luis G. Paz-Ares, MD, PhD, Summarizes Results of the CheckMate 057 Trial on Nonsquamous Cell NSCLC
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario Doce De Octubre, discusses the superior overall survival in patients taking nivolumab vs docetaxel in advanced nonsquamous NSCLC (Abstract LBA109).
Laurie Helen Sehn, MD, MPH, Summarizes Results of the GADOLIN Trial on Indolent NHL
Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).
Matthew J. Loscalzo, LCSW, on The Effects of Gender on Patients’ Coping Strategies and Stress Management
Matthew J. Loscalzo, LCSW, of the City of Hope, discusses the ways in which a person’s gender influences how he or she reacts to and copes with a cancer diagnosis and treatment.
Allison J. Applebaum, PhD, and William S. Breitbart, MD, on Creating Meaning-Centered Psychotherapy for Cancer Patients
Allison J. Applebaum, PhD, and William S. Breitbart, MD, of Memorial Sloan Kettering Cancer Center, discuss the early days of this new treatment for despair and distress in cancer patients.
Allison J. Applebaum, PhD, and William S. Breitbart, MD, on Workshops in Meaning-Centered Psychotherapy
Allison J. Applebaum, PhD, and William S. Breitbart, MD, of Memorial Sloan Kettering Cancer Center, discuss a meaning-centered psychotherapy workshop they conducted for an international group of clinicians.
Allison J. Applebaum, PhD, and William S. Breitbart, MD, on Adapting Meaning-Centered Psychotherapy for Caregivers
Allison J. Applebaum, PhD, and William S. Breitbart, MD, of Memorial Sloan Kettering Cancer Center, explain how they brought this new treatment to help stressed caregivers of loved ones with cancer.
Jimmie C. Holland, MD, and Tammy A. Schuler, PhD, on Talking With Patients About Their Distress: A Demonstration
Jimmie C. Holland, MD, of Memorial Sloan Kettering Cancer Center, and Tammy A. Schuler, PhD, of the Association for Behavioral and Cognitive Therapies, demonstrate a dialogue between a clinician and a recently diagnosed cancer patient whose distress was discovered with the use of the Distress...
Mark Lazenby, PhD, APRN, FAPOS, on Distress Screening in the Community Setting
Mark Lazenby, PhD, APRN, FAPOS, of the Yale School of Nursing, discusses the APOS–ACCC project to screen for psychosocial distress in community cancer centers. These model programs improve patient care and the patient experience.
Jeff Dunn, AO, PhD, GAICD, on Community-Based Response to Cancer
Jeff Dunn, AO, PhD, GAICD, of the Cancer Council Queensland, discusses reducing the burden of cancer on individuals and communities.
Allison J. Applebaum, PhD, and William S. Breitbart, MD, on Meaning-Centered Psychotherapy for Cancer Patients
Allison J. Applebaum, PhD, and William S. Breitbart, MD, of Memorial Sloan Kettering Cancer Center, discuss a powerful treatment approach that is grounded in a moving personal story.
Robert T. Croyle, PhD, on The 2015 NCI Initiative Expanding Health Care Delivery Research
Robert T. Croyle, PhD, of the National Cancer Institute, discusses the research program on the variation in the quality of cancer care, our ability to monitor quality and measure outcomes, and understand the psychosocial aspects of care.
Patricia A. Ganz, MD, on Incorporating Psychosocial Services for Quality Cancer Care
Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses the Institute of Medicine report on patient-centered care, its relation to psychosocial services, and the role IPOS/APOS members can play.
Irene Higginson, MD, on Palliative and End-of-Life Care: An International Perspective
Irene Higginson, MD, of Cicely Saunders International, discusses the goals of psychosocial palliative care for patients around the world with advanced cancer.
Wendy Lichtenthal, PhD, and David Kissane, MD, on Models of Family-Centered Care During Palliative Care and Bereavement
Wendy Lichtenthal, PhD, of Memorial Sloan Kettering Cancer Center, and David Kissane, MD, of Monash University, discuss the importance of and challenges with attending to the whole family during palliative care.
Andrea F. Patenaude, PhD, on Standards for Psychosocial Care of Children With Cancer
Andrea F. Patenaude, PhD, of Dana-Farber Cancer Institute, discusses the challenges to implementing standards for pediatric and adolescent psycho-oncology and looks ahead at next steps in the field.
Christopher J. Recklitis, PhD, MPH, on The Risk of Suicide After a Cancer Diagnosis
Christopher J. Recklitis, PhD, MPH, of the Dana-Farber Cancer Institute, discusses what is known about suicide after cancer, the risks faced by prostate cancer patients within the first year after diagnosis, and challenges across the treatment trajectory
Julia H. Rowland, PhD, on The Psychosocial Challenges Cancer Survivors Face
Julia H. Rowland, PhD, of the National Cancer Institute, discusses the growing number of promising interventions to improve health and function for those living with and beyond a cancer diagnosis, as well as those who care for and about them.
Lori Wiener, PhD, DCSW, LCSW-C, and Karen Fasciano, PsyD, on Psycho-Oncology: Where the Field Is Headed
Lori Wiener, PhD, DCSW, LCSW-C, of the National Cancer Institute, and Karen Fasciano, PsyD, of the Dana-Farber Cancer Institute, discuss the challenges of the art and science of psycho-oncology.
Lori Wiener, PhD, DCSW, LCSW-C, and Paul B. Jacobsen, PhD, on IPOS-APOS Themes of This Year’s Meeting
Lori Wiener, PhD, DCSW, LCSW-C, of the National Cancer Institute, and Paul B. Jacobsen, PhD, of the Moffitt Cancer Center, discuss the highlights of this year’s meeting, which for the first time brings together the international and American psychosocial oncology societies.
Bradley J. Zebrack, PhD, and Ursula Sansom-Daly, PhD, on Global Psychosocial Standards of Care for Adolescents and Young Adults With Cancer
Bradley J. Zebrack, PhD, of the University of Michigan School of Social Work, and Ursula Sansom-Daly, PhD, of the University of New South Wales, talk about providing supportive care services that meet the unique needs of adolescents and young adults with cancer.
Ramaswamy Govindan, MD: Roundup of Lung Cancer Findings
Ramaswamy Govindan, MD, of Washington University, summarizes three important papers: ROVA-T in relapsed and refractory small cell lung cancer, genomic characterization of large-cell neuroendocrine tumors, and the ECOG study on bevacizumab following chemotherapy for resected non–small cell lung...
Guneet Walia, PhD, on Central Issues in Lung Cancer Care
Guneet Walia, PhD, of the Lung Cancer Foundation, summarizes some key presentations: bridging the quality chasm, patients’ attitudes and physicians’ perceptions on maintenance therapy, and patient advocacy.
Jennifer King, PhD: Scientific Perspectives From the Lung Cancer Alliance
Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and advances in immunotherapy.
Everett E. Vokes, MD, on Controversies in Stage IIIA Disease
Everett E. Vokes, MD, of the University of Chicago, summarizes expert views on treating stage IIIA disease: decision-making in selecting patients for surgery; multiple-modality choices; and using induction chemotherapy (Abstract ED10).
Naiyer A. Rizvi, MD, on Immune Checkpoint Inhibitors
Naiyer A. Rizvi, MD, of Columbia University, offers an update on immune checkpoint inhibitors in non–small cell lung cancer: what’s new and what’s next.
Nagashree Seetharamu, MD, on Anti-Glycan Antibody Profiling in De Novo Stage IV Non Small Cell Lung Cancer
Nagashree Seetharamu, MD, of the North Shore LIJ Health System, discusses serum AGA-signatures that may provide a minimally invasive test for early detection of lung cancer risk (Abstract P3.04-085).
William D. Travis, MD, on Pathology and Genetics of Lung Tumors: 2015 WHO Classification
William D. Travis, MD, of Memorial Sloan Kettering Cancer Center, gives an update on the WHO classification, which is crucial for optimal personalized treatment of lung cancer patients (Abstract PLEN02.01).
Fred R. Hirsch, MD, PhD, and Paul A. Bunn, Jr., MD, on the Highlights of the World Conference on Lung Cancer
Fred R. Hirsch, MD, PhD, of the University of Colorado Health Science Center, and Paul A. Bunn, Jr, MD, of the University of Colorado Cancer Center, give their views on the goals and important presentations of the 2015 World Conference on Lung Cancer.
Karen Kelly, MD, on PD-1 Axis Inhibition and the Treatment of Advanced Disease
Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or...
Philip Bonomi, MD, on SBRT and Surgery for Localized Disease
Philip Bonomi, MD, of Rush Medical College, summarizes a debate on two important issues: choosing between surgery and stereotactic body radiation therapy (SBRT) in operable NSCLC, and whether or not to use SBRT for nonbiopsied lung nodules (Abstract PC 01).
Philip Bonomi, MD, on Results of the Romana 1 and Romana 2 Trials
Philip Bonomi, MD, of Rush Medical College, summarizes the findings on anamorelin and its use in advanced NSCLC for improvement in anorexia/cachexia symptoms (Abstracts ORAL 29.01, ORAL 29.02).
Ugo Pastorino, MD, on Reducing Lung Cancer Mortality
Ugo Pastorino, MD, of the Istituto Nazionale dei Tumori Foundation, discusses his study, which showed that stopping smoking before or during low-dose computed tomography screening reduced overall mortality by more than 25%, a benefit that is three- to fivefold greater than this type of screening...
Pasi A. Jänne, MD, PhD, on Integration of Next Generation Data Into the Clinic
Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, summarizes a workshop he conducted on the state of the art in next-generation sequencing of lung cancer (Abstract WS 01.07).
James R. Jett, MD, on Screening With Early CDT and CT
James R. Jett, MD, of National Jewish Health, discusses his study of the early CDT-Lung biomarker. His hypothesis: When used in combination with low-dose CT in screening of a high-risk population, this biomarker would increase the detection of early-stage lung cancer (Abstract MINI 12.11).
Vassiliki Papadimitrakopoulou, MD, on The Lung MAP Clinical Trial
Vassiliki Papadimitrakopoulou, MD, of MD Anderson Cancer Center, discusses the ways in which patients, investigators, and pharmaceutical companies are working together to accelerate research and access to care (Abstract MTE 02.01).
James L. Mulshine, MD, on Lung Cancer Screening in the United States: Can It Happen?
James L. Mulshine, MD, of Rush University Medical Center, discusses the profound challenges of implementing national CT screening to ensure delivery of high-quality, best-practice early lung cancer detection in the target population of tobacco-exposed individuals (Abstract MS 15.01).
Christine D. Berg, MD, on Screening for Lung Cancer in Those at High Risk
Christine D. Berg, MD, of Johns Hopkins Medicine, discusses how increased insurance coverage should dramatically increase lung cancer screening. If done correctly—which will be a challenge—screening will help improve the prognosis of patients with lung cancer (Abstract PLEN 01.01).
Alice T. Shaw, MD, PhD, on ALK, Crizotinib, and Alectinib
Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, summarizes efficacy and safety data from studies on crizotinib, brigatinib, and alectinib for ALK-positive non–small cell lung cancer (ORAL 33.03, 33.06, 33.07).
Heather A. Wakelee, MD, on Results of the E1505 Clinical Trial
Heather A. Wakelee, MD, of Stanford University discusses the study that explored the question of whether adding bevacizumab to adjuvant chemotherapy is beneficial in the setting of resected non–small cell lung cancer (Abstract PLEN04.03).
Tony Mok, MD, and Fred R. Hirsch, MD, PhD: Summary of the IASLC Presidential Symposium
Tony Mok, MD, of The Chinese University of Hong Kong, and Fred R. Hirsch, MD, PhD, of University of Colorado Health Science Center discuss the highlights of the featured plenary session, which included the conference’s top four abstracts (Abstract PLEN04).
Roy S. Herbst, MD, PhD, on Results From SWOG S0819
Roy S. Herbst, MD, PhD, of the Smilow Cancer Hospital at Yale Cancer Center, discusses his findings of a phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in advanced non–small cell lung cancer (Abstract PLEN04.01).
Silvia Novello, MD, PhD: Lung Cancer Is a Women's Disease Too
Silvia Novello, MD, PhD, of the University of Turin, discusses a much-neglected aspect of lung cancer: It is not just the province of men; women are affected in great numbers as well.
Barbara J. Gitlitz, MD: Genomics of Young Lung Cancer Study
Barbara J. Gitlitz, MD, of USC/Norris Cancer Center, discusses the first prospective study on the genomic drivers and demographics of lung cancer in patients under 40 who took part in the study remotely via the Internet (Abstract ORAL22.05).
Howard Jack West, MD, on New Kinase Targets for Treating Advanced NSCLC
Howard Jack West, MD, of the Swedish Cancer Institute, summarizes three important papers: anlotinib as third-line treatment for refractory advanced non–small cell lung cancer; the EGFR exon 20 mutation as a prognostic/predictive biomarker; and EGFR exon 18 mutations as molecular predictors of...
Eric Lim, MD, on Increasing Incidence of Non-Smoking Lung Cancer
Eric Lim, MD, of the Royal Brompton and Harefield NHS Trust, discusses his findings on the nonspecific symptoms of never-smokers, which suggests that imaging could play a more important role in diagnosing these patients at an earlier stage.
Lorraine Cheryl Pelosof, MD, PhD, on Never-Smokers in NSCLC
Lorraine Cheryl Pelosof, MD, PhD, of UT Southwestern Medical Center, discusses her study findings, which demonstrate an increasing proportion of never-smokers among patients with non–small cell lung cancer (Abstract ORAL 22.01).
M. Catherine Pietanza, MD, on A Promising New Agent for SCLC
M. Catherine Pietanza, MD, of Memorial Sloan Kettering Cancer Center, discusses rovalpituzumab tesirine, a promising DLL3-targeted antibody drug conjugate, the first precision treatment for small cell lung cancer (Abstract 7LBA).
Benjamin Besse, MD, PhD, and Tony Mok, MD, on Results of the BIRCH Clinical Trial
Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss this phase II trial of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1–selected NSCLC (Abstract 17LBA).
Martine Frouws, MSc, PhD, on Postdiagnosis Aspirin and Improved Survival in All GI Cancers
Martine Frouws, MD, PhD Candidate, of Leiden University Medical Centre discusses her study, which showed a significant increase in overall survival among patients with GI cancers who took aspirin compared to those who did not (Abstract 2306).
